Shanghai Yuanxi Pharmaceutical Technology Co., Ltd.

Primary purpose: To evaluate the safety of porselenin combined with radiotherapy in the treatment of patients with primary postoperative high-grade spinal glioma; Secondary purpose: To evaluate the multiple-dose PK characteristics of porselenin combined with radiotherapy in the treatment of patients with primary postoperative high-grade spinal glioma; Exploratory purpose: To evaluate the preliminary effectiveness of porselenin combined with radiotherapy in the treatment of patients with primary postoperative high-grade spinal glioma; To explore the biomarkers of porselenin combined with radiotherapy in the treatment of patients with primary postoperative high-grade spinal glioma.

Primary objective: To evaluate the safety of standard therapy (determined by the investigator) combined with porselenin tablets in patients with fibrotic interstitial lung disease; Secondary objective: To evaluate the single and multiple dose PK characteristics of standard therapy (determined by the investigator) combined with porselenin tablets in patients with fibrotic interstitial lung disease; Exploratory objective: To evaluate the preliminary effectiveness of standard therapy (determined by the investigator) combined with porselenin tablets in the treatment of fibrotic interstitial lung disease; To explore the biomarkers of standard therapy (determined by the investigator) combined with porselenin tablets in the treatment of fibrotic interstitial lung disease

This study is divided into 2 sub-studies, and the purpose of each study is as follows: Purpose of single-dose study: Primary purpose: to evaluate the safety and tolerability of BS1801 after a single oral administration. Secondary purpose: to evaluate the pharmacokinetic characteristics of BS1801 after a single oral administration. Purpose of multiple-dose study: Primary purpose: to evaluate the safety and tolerability of BS1801 after multiple oral administration. Secondary purpose: to evaluate the pharmacokinetic characteristics of BS1801 after multiple oral administration.